Remogliflozin etabonate 100 and 250 mg achieved greater reductions in glycated hemoglobin (HbA1c) and demonstrated noninferiority in reducing HbA1c levels compared with dapagliflozin 10 mg over 24 weeks.

The use of rescue medication was lower, and the proportion of patients achieving therapeutic glycemic response was higher, in patients receiving remogliflozin etabonate.

Reductions in blood glucose levels and bodyweight were also similar among the three study groups. No severe adverse events were observed.

Remogliflozin etabonate could be an effective and well-tolerated alternative treatment option for glycemic control in patients with type 2 diabetes mellitus.